Managing chronic kidney disease in type 2 diabetes in family practice

Journal of the National Medical Association

Volumn 103, Issue 9-10, 2011, Pages 952-959

  Scott, David ^a,b   Davidson, Jaime A ^c  

^a Clinical Research Development Associates   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Kidney; Nephropathy

Indexed keywords

ACARBOSE; AMLODIPINE; ATORVASTATIN; CAPTOPRIL; ENALAPRIL; EXENDIN 4; FLUINDOSTATIN; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; IRBESARTAN; LIRAGLUTIDE; LOSARTAN; METFORMIN; MEVINOLIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; PRAVASTATIN; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; ROSUVASTATIN; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; TRANDOLAPRIL; UNINDEXED DRUG; VERAPAMIL; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; DYSLIPIDEMIA; GENERAL PRACTICE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; KIDNEY INJURY; MACROALBUMINURIA; MICROALBUMINURIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME; BLOOD; CHRONIC KIDNEY FAILURE; COMORBIDITY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HYPERCHOLESTEROLEMIA;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FAMILY PRACTICE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC;

EID: 84858841002     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30452-1     Document Type: Article

References (81)

1. Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5:673-682.
2. National Kidney Foundation. Chronic kidney disease (CKD). www.kidney.org/kidneydisease/ckd/index.cfm#whatis. Accessed June 22, 2011.
3. Collins A, Foley R, Chavers B, et al. National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. www.usrds.org/atlas.htm. Accessed June 22, 2011.
4. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(suppl 2):S12-S154.
5. National Institute of Diabetes and Digestive and Kidney Diseases, National Kidney Disease Education Program. Chronic kidney disease (CKD) information. www.nkdep.nih.gov/professionals/chronic-kidney-disease. htm#definition. Accessed June 22, 2011.
6. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225-232. (Pubitemid 35463925)
7. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke. 1996;27:2033-2039. (Pubitemid 26372576)
8. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160:1093-1100. (Pubitemid 30227018)
9. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157:1413-1418. (Pubitemid 27300386)
10. United Kingdom Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
11. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 2011;34(suppl 1):S11-S61.
12. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273-3277. (Pubitemid 37430080)
13. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
14. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
15. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
16. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(suppl 2):B21-B29. (Pubitemid 30185774)
17. Levin SR, Coburn JW, Abraira C et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care. 2000;23:1478-1485.
18. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572. (Pubitemid 351831357)
19. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559. (Pubitemid 351831356)
20. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003;17:7-12. (Pubitemid 36163426)
21. Imano E, Kanda T, Nakatani Y et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care. 1998;21:2135-2139. (Pubitemid 28549163)
22. Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism. 2001;50:1193-1196. (Pubitemid 33034703)
23. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2009.
24. Amaryl [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; 2009.
25. Actos [package insert]. Deerfield, IL: Takeda Pharmaceuticals America Inc; 2009.
26. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
27. Prandin [package insert]. Princeton, NJ: Novo Nordisk Inc; 2010.
28. Starlix [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
29. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2010.
30. Victoza [package insert]. Princeton, NJ: Novo Nordisk Inc; 2011.
31. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2010.
32. Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2009.
33. Precose [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2008.
34. Glyset [package insert]. New York, NY: Pharmacia & Upjohn Co; 2010.
35. Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2009.
36. Apidra [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; 2009.
37. Humalog [package insert]. Indianapolis, IN: Eli Lilly & Co; 2010.
38. NovoLog [package insert]. Princeton, NJ: Novo Nordisk Inc; 2010.
39. Lantus [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; 2010.
40. Levemir [package insert]. Princeton, NJ: Novo Nordisk Inc; 2009.
41. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract. 2010;16:1-31.
42. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-1097. (Pubitemid 34175478)
43. Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens. 1996;10:185-192. (Pubitemid 26144471)
44. Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ. 1992;305:981-985.
45. Chan JC, Ko GT, Leung DH, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 2000;57:590-600. (Pubitemid 30430651)
46. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577-581. (Pubitemid 23102690)
47. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996;156:286-289. (Pubitemid 26058479)
48. Schnack C, Hoffmann W, Hopmeier P, Schernthaner G. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia. 1996;39:1611-1616. (Pubitemid 26397376)
49. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens. 1995;8:876-883.
50. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
51. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs. 2002;62:787-816. (Pubitemid 34494023)
52. Weir MR, Smith DH, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens. 2001;14(7 Pt 1):665-671. (Pubitemid 32612531)
53. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961. (Pubitemid 39447136)
54. Brenner BM, Cooper ME, de ZD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
55. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
56. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003;14:992-999. (Pubitemid 36359280)
57. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
58. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
59. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002. (Pubitemid 38669986)
60. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-1951. (Pubitemid 39447135)
61. Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int Suppl. 1994;45:S161-S164.
62. Sano T, Hotta N, Kawamura T, et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Diabet Med. 1996;13:120-124. (Pubitemid 26074289)
63. Cordonnier DJ, Pinel N, Barro C, et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol. 1999;10:1253-1263. (Pubitemid 29246990)
64. Andersen S, Brochner-Mortensen J, Parving HH. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003;26:3296-3302. (Pubitemid 37466890)
65. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16:3748-3754. (Pubitemid 46211298)
66. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest. 2000;30:980-987.
67. Lipitor [package insert]. New York, NY: Parke-Davis Division of Pfizer Inc; 2011.
68. Lescol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2009.
69. Lovastatin [package insert]. Princeton, NJ: Sandoz Inc; 2006.
70. Livalo [package insert]. Montgomery, AL: Kowa Pharmaceuticals America Inc; 2010.
71. Pravachol [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2007.
72. Crestor [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.
73. Simvastatin [package insert]. Jacksonville, FL: Ranbaxy Pharmaceuticals Inc; 2006.
74. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393. (Pubitemid 36159355)
75. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):S79-S83.
76. Ismail N, Neyra R, Hakim R. The medical and economical advantages of early referral of chronic renal failure patients to renal specialists. Nephrol Dial Transplant. 1998;13:246-250. (Pubitemid 28062179)
77. Yokoyama Y, Yamazaki S, Hasegawa T, et al. Impact of early referral to nephrologist on mental health among hemodialysis patients: a Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin Pract. 2009;113:c191-c197.
78. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137:479-486. (Pubitemid 35024618)
79. de Jager DJ, Voormolen N, Krediet RT, Dekker FW, Boeschoten EW, Grootendorst DC. Association between time of referral and survival in the first year of dialysis in diabetics and the elderly. Nephrol Dial Transplant. 2010;26:652-658.
80. Tseng CL, Kern EF, Miller DR, et al. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. Arch Intern Med. 2008;168:55-62.
81. Rodbard HW, Jellinger PS, Davidson JA, et al. American Association of Clinical Endocrinologists/American College of Endocrinology. AACE/ACE diabetes algorithm for glycemic control. www.aace.com/pub/pdf/ GlycemicControlAlgorithmPPT.pdf. Accessed June 22, 2011.